August 06, 2015
1 min read

Tiotropium safe, effective for asthma in adolescents

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Tiotropium administered via an inhaler appeared effective and safe in adolescents with moderate to severe asthma, according to study results.

Gustavo J. Rodrigo, MD, from the department of emergency at Hospital Central de las Fuerzas Armadas in Uruguay, and colleagues conducted a systematic review of placebo-controlled, randomized trials from Medline, Embase, CINAHL, SCOPUS and Cochrane to determine the efficacy and safety of inhaled tiotropium in adolescents with moderate to severe asthma.

Gustavo J. Rodrigo

Gustavo J. Rodrigo

The analysis included three studies of 895 patients aged 12 to 18 years.

Tiotropium appeared to improve peak forced expiratory volume in 1 second (FEV1) by 120 mL and trough FEV1 by 100 mL from baseline results (P < .001 for both).

Tiotropium also appeared to decrease the number of patients with at least one exacerbation (17.6%) compared with placebo (23.8%).

Minimal differences between rescue medication use, withdrawals and withdrawals due to adverse events (27.3% vs. 27.1%) occurred.

“This systematic review of tiotropium for adolescents with symptomatic moderate to severe asthma suggests that tiotropium administered via an inhaler is well tolerated and efficacious as an addition to maintenance treatment with [inhaled corticosteroids] or [inhaled corticosteroids] plus [long-acting beta agonist],” the researchers wrote. “Available data do not suggest an advantage of the 5 µg once-daily dose compared with the 2.5 µg once-daily dose.” – by Ryan McDonald

Disclosure: Rodrigo reports receiving lecture, speaker and adviser fees from Air Products & Chemicals Inc., Almiral, AstraZeneca and Boehringer Ingelheim. Please see the full study for a list of all other relevant financial disclosures.